We have reported evidence for the presence of ChAT in human extracellular fluids (Vijayaraghavan et al., 2013) and shown that treatment with galantamine in AD patients resulted in changes in ChAT and AChE in cerebrospinal fluid (CSF) compared with placebo (Karami et al., 2019). This evidence concerns the gene ACHE and Alzheimer disease.